Q1 2018 13F Holders as of 31 Mar 2018
-
Type / Class
-
Debt / NOTE 2.000% 8/1
-
Market price (% of par)
-
77.34%
-
Total 13F principal
-
$323,422,000
-
Principal change
-
-$1,558,000
-
Total reported market value
-
$252,271,000
-
Number of holders
-
14
-
Value change
-
-$1,339,655
-
Number of buys
-
2
-
Number of sells
-
4
Institutional Holders of AEGERION PHARMACEUTICALS INC - NOTE 2.000% 8/1 as of Q1 2018
As of 31 Mar 2018,
AEGERION PHARMACEUTICALS INC - NOTE 2.000% 8/1 was held by
14 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$323,422,000
in principal (par value) of the bond.
The largest 10 bondholders included
Athyrium Capital Management, LP, EdgePoint Investment Group Inc., HIGHBRIDGE CAPITAL MANAGEMENT LLC, Allianz Asset Management GmbH, UBS OCONNOR LLC, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), ORBIMED ADVISORS LLC, Tekla Capital Management LLC, AMERIPRISE FINANCIAL INC, and BAKER BROS. ADVISORS LP.
This page lists
14
institutional bondholders reporting positions
for the Q1 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.